Inclusion Criteria:  Patients 5 years to 21 years of age, inclusive, with inflammatory bowel disease receiving infliximab therapy. Patient or Parent/legal guardian has signed informed consent form and patient has provided written or oral assent (if applicable) Patients who have completed the induction course of infliximab (treated for at least 14 weeks of infliximab)  Patients should be in stable clinical status.  Clinical status will be assessed by the treating physician and defined as symptom free (full responder) or clear clinical improvement, but clinical symptoms still present (partial responder). Concomitant immunomodulators are allowed, which may include medications like azathioprine, methotrexate, or oral corticosteroids at a low dose(defined as 0.5 mg/kg or ≤ 20 mg if subject weights above 40 kg) if kept stable throughout the study.  Exclusion Criteria:  Patients younger than 5 years of age or older than 21 years of age. Patients who are not on maintenance therapy of infliximab. Patients who, at screening, have infliximab antibody levels greater than 1000 ng/mL, which was previously shown to be a clinically relevant cut-off. Patients who fail to respond to infliximab.  Patients who are unable to complete the entire study.  Patients who have an antibody level > 1000 ng/mL. Patients who, in the opinion of the investigator, are unlikely to be able to complete the requirements of the study. Failure to respond to current medical management based on clinical assessment.